ORCA Therapeutics strengthens its Patent Portfolio
September 06, 2012
Amsterdam, The Netherlands – September 6th, 2012 – ORCA Therapeutics BV, a pioneer in the development of innovative virotherapies for treatment of cancer, announced today that it has expanded its patent portfolio on oncolytic viruses with patent no. EP1466001 entitled, ”Viruses with enhanced lytic potency”, granted by the European Patent Office. This patent covers oncolytic adenoviruses expressing proteins of the p53-dependent apoptosis pathway. The expression of such proteins was shown to increase the lytic capacity of oncolytic adenoviruses in tumor cells lacking a functional p53-dependent apoptosis pathway.
br> A corresponding patent was previously granted in the US (US8052965). These patents are assigned to the Vereniging voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek en Patiëntenzorg (VUmc) and licensed exclusively to ORCA Therapeutics.
"Strengthening the breadth and depth of our intellectual property portfolio is key to create value and provides the foundation for extension of our product pipeline of highly innovative oncolytic adenoviruses," said Janneke Meulenberg, Chief Executive Officer of ORCA Therapeutics. "With the EP and US patents in hand, we have patent protection for next generation products based on our p53 technology in the largest pharmaceutical markets in the Western World”.
About ORCA Therapeutics
ORCA Therapeutics BV is a biopharmaceutical company developing a pipeline of innovative anticancer therapies based on the highly promising approach of Oncolytic Replication Competent Agents (ORCA). ORCA Therapeutics’ technology and IP portfolio originates from the research performed at the Department of Medical Oncology at the VU University Medical Center (VUmc) in Amsterdam, the Netherlands. The company has a platform of technologies that are predominantly based on highly engineered oncolytic adenoviruses. ORCA Therapeutics is currently preparing its lead product ORCA-010 for testing in clinical trials.
For more information, please contact:
ORCA Therapeutics BV
Janneke Meulenberg, CEO